

Great Science.
Deep Compassion.
Real Impact.



At Alkermes, we apply our deep neuroscience expertise as we seek to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. With our portfolio of marketed medicines and investigational pipeline candidates, we seek to make a meaningful difference in the way people manage their diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized.


Marketed Medicines

Our portfolio of proprietary commercial products focuses on chronic conditions that represent some of the most challenging health issues of our time. We currently market commercial products focused on these complex diseases:

- Alcohol Dependence
- Opioid Dependence
- Schizophrenia
- Bipolar I Disorder


Company Info

- Founded: 1987
- Total Employees: Approx. 2,200 worldwide




Our Pipeline

We apply our scientific strengths to develop medicines focused in neuroscience. Our investigational product candidates include:



These programs are investigating treatments or indications that have not received approval from a health authority. The information presented is not intended to convey conclusions of safety or efficacy. There is no guarantee that the outcome of these studies will result in approval by a health authority. Last updated: November 2023





Responsibility

Responsibility is intrinsic to our work as we focus on some of the most pressing health issues of our time. Within this broader context, we are committed to further enhancing our responsibility and sustainability strategy and regularly evaluating the ways we monitor and report on these efforts.

We strive to positively impact the lives of our employees, members of our communities and society at large. We support research, education and patient advocacy programs that we believe have high potential to benefit people affected by diseases in our therapeutic areas of focus, while also giving back to the communities in which we live and work through employee volunteerism and charitable giving.



"In addition to our medicines and research efforts, we see ourselves having a responsibility and opportunity to contribute more broadly and serve as a positive example for others."

-Richard Pops, CEO



Alkermes employees participated in Alkermes in Action volunteer events in 2023

Connect With Us

- X @Alkermes
- in [linkedin.com/company/alkermes/](https://www.linkedin.com/company/alkermes/)
- globe www.alkermes.com

- Media Relations: mediainfo@alkermes.com
- Investor Inquiries: investor_relations@alkermes.com
- Business Development: busdev@alkermes.com

